Monday, November 06, 2017 3:35:04 PM
The stock price is very frustrating but the other penny stocks in the sector have higher valuations mostly because they're pumping away. They're not ahead of Nemus in drug development. InMed has probably spent $200k pumping their biosynthesis story for a year like they're the only ones doing it and I think there's been some insider selling lately. Nemus should now have enough money to get into Phase II for their leading drug candidate that seems to have a high probability of being approved. Hardly a dead company.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM